New research reveals that patients with coronary artery disease who were treated with a drug designed to increase HDL or good cholesterol levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo. The research was conducted by the Cleveland Clinic Coordinating Center for Clinical Research (C5Research). The drug, RVX-208, induces the production of apolipoprotein A1 (apoA1), a major protein in HDL. Prior research has ...
Read More
No comments:
Post a Comment